SLN · Silence Therapeutics plc
Market Cap
$694.88M
Shares
62.15M
Volume · Oct 5
976.32K
Avg daily vol (3M)
1.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.64
Open$10.77
Day$10.38–10.78
52W close$4.30–15.43
Avg vol 30d813K
Short int2.2M · 3.5% float · 2.5d
Short vol45%
Last earningsFeb 27, 2025
DataSep 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held Feb 27, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$615,000
Trailing 12 months
Net income (TTM)
−$59.95M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-11,106.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$72.05M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+104.6%
Trailing year
Short interest
3.5%
Latest settlement · 2.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
−16%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
57%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
+77%
trailing
YTD return
+75%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+29% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.50% of float · ▼ -10.6% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−99%
Y/Y
Gross margin
62%
contracting
EPS growth
−91%
Y/Y
Free cash flow
$-62.3M
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+29% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.50% of float · ▼ -10.6% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $11 · 57%
Range high $15
vs 200-day avg +30%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLN
this stock
Silence Therapeutics plc
|
$694.88M | +75.0% | -98.7% | — | 3.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLN | -4.8% | -28.1% | +77.2% | -2.7% | +75.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.6% | -27.6% | +65.0% | -3.6% | +62.1% |